Table 6.
Association of post-diagnosis bisphosphonate use with risk of breast cancer mortality.
| Person-years at risk | Died from Breast Cancer | Rate per 1000 p-y | HR (95% CI) 1 | |
|---|---|---|---|---|
| Bisphosphonate Use | ||||
| Never BP use2 | 20665 | 288 | 13.9 | 1.00 (ref) |
| Ever BP use | 3289 | 20 | 6.1 | 0.48 (0.30–0.75) |
| Duration of bisphosphonate use | ||||
| Never BP use2 | 20665 | 288 | 13.9 | 1.00 (ref) |
| >1 month to < 1 year | 657 | 7 | 10.7 | 0.76 (0.36–1.61) |
| 1 or more years | 2632 | 13 | 4.9 | 0.40 (0.23–0.69) |
| HR for each continuous year of use | 0.75 (0.62–0.90) | |||
| Duration by timing of first bisphosphonate use | ||||
| Never BP use2 | 20665 | 288 | 13.9 | 1.00 (ref) |
| >1 month to < 1 year | 657 | 7 | 10.7 | 0.76 (0.36–1.61) |
| 1 or more years, 1st use 3 or more years post-dx | 1459 | 9 | 6.2 | 0.53 (0.27–1.05) |
| 1 or more years, 1st use within 3 years post-dx | 1173 | 4 | 3.4 | 0.25 (0.09–0.67) |
1
Adjusted for age and source study (the original three studies through which women were ascertained); Hazard Ratio (HR), Confidence Interval (CI)
2
Never use defined as no report of use or one reported instance of use (one month); Ever use defined as greater than one reported instance of use